Fosamax and Osteonecrosis of the Jaw: Understanding the Pathophysiology

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Medication Risks

The legacy heritage of general health and science information dissemination has long provided a foundational understanding of human physiology and disease prevention. This broad context naturally includes discussions on medication safety and adverse effects, where public awareness campaigns have historically focused on common risks and general precautions. Within this framework, the transition to a more specific occupational exposure concern begins by narrowing the scope from population-wide health education to the particular circumstances of individuals in industrial or manufacturing settings. In mass production environments, workers may encounter unique chemical or material exposures that differ from typical consumer or patient scenarios. The pivot occurs when considering how routine health information, which often addresses medication use in a clinical or domestic context, must be adapted to account for the distinct variables present in occupational roles. For instance, the general principle of drug safety takes on added complexity when the individual’s daily environment includes repeated contact with industrial compounds or physical stressors. This shift does not introduce specific disease mechanisms but rather reframes the inquiry: from a general understanding of how pharmaceuticals interact with the body, to a focused examination of how workplace conditions might modify that interaction. The concern thus moves from abstract health literacy to a practical assessment of risk factors inherent in specific job functions, setting the stage for a deeper exploration of exposure pathways without yet detailing pathophysiological outcomes.

Bridging to Fosamax and Jaw Health

Building on the general framework of medication safety, we now focus on a specific drug and its serious adverse effect. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. However, this suppression of normal bone remodeling has been linked to a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Pathophysiology: How Fosamax Triggers Osteonecrosis of the Jaw

The pathophysiology of how Fosamax triggers ONJ involves a complex interplay of drug-induced changes in bone metabolism and local factors in the jaw. The jawbone has unique structural and metabolic characteristics that make it particularly susceptible to bisphosphonate-related complications. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including postmenopausal osteoporosis and bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies using animal models have examined the effects of bisphosphonate treatment on jawbone properties. In estrogen-deficient rats, treatment with bisphosphonate (alendronate) was evaluated through multiscale characterization including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These investigations help elucidate how bisphosphonates alter the mechanical and structural integrity of jawbone tissue. The mechanistic pathway linking Fosamax to ONJ begins with the drug's potent inhibition of osteoclast activity. Osteoclasts are responsible for bone resorption, a process essential for normal bone turnover, repair of microdamage, and healing after dental procedures. By suppressing osteoclast function, Fosamax reduces the jawbone's ability to remodel and repair itself. This is particularly problematic in the jaw, which undergoes constant mechanical stress from chewing and is frequently exposed to oral bacteria. When a patient undergoes an invasive dental procedure such as tooth extraction or dental implant placement, the normal healing response is impaired. The reduced bone turnover prevents proper formation of new bone at the extraction site, leading to delayed healing and exposure of necrotic bone.

Risk Factors and Clinical Evidence

Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This suggests that cumulative drug exposure over time progressively impairs bone healing capacity. The timeline between exposure to Fosamax and documented harm varies considerably. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This wide range indicates that ONJ can develop relatively quickly in some patients, while others may take months to show symptoms. The variability likely depends on individual risk factors, such as pre-existing dental disease or the timing of invasive dental procedures. In placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting that ONJ is a relatively rare event in clinical trial populations. However, post-marketing surveillance has identified cases, and the label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation and Warning Adequacy

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and the development of ONJ, excluding other potential causes such as cancer or radiation therapy, and documenting the clinical course. The label notes that most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern of improvement upon discontinuation and recurrence upon rechallenge supports a causal relationship. The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw (Section 5.4) that describes the condition, associated risk factors, and management recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The warnings highlight that ONJ can occur spontaneously but is generally associated with dental procedures or infection, and they list known risk factors. The label also advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that long-term use carries cumulative risk. In summary, Fosamax triggers osteonecrosis of the jaw through suppression of bone remodeling in the jawbone, impairing healing after dental procedures or in the presence of infection. The risk is influenced by duration of exposure, concomitant therapies, and oral health status. The timeline for onset is variable, and the condition may improve with drug discontinuation. Warnings in the prescribing information address these risks, but patients and healthcare providers should remain vigilant, especially when invasive dental procedures are planned.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast activity, which suppresses bone remodeling. In the jaw, this impairs healing after dental procedures or infections, leading to bone necrosis. The jawbone's unique structure and constant mechanical stress make it particularly vulnerable (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ develop?

The time to onset varies from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It depends on individual risk factors and whether invasive dental procedures are performed.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.